Cargando…

Randomized Clinical Trial on the Effect of Bardoxolone Methyl on GFR in Diabetic Kidney Disease Patients (TSUBAKI Study)

INTRODUCTION: Bardoxolone methyl significantly increases estimated glomerular filtration rate (eGFR) in patients with chronic kidney disease (CKD). However, the phase 3 study, Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus: the Occurrence of Renal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nangaku, Masaomi, Kanda, Hironori, Takama, Hirotaka, Ichikawa, Tomohiro, Hase, Hiroki, Akizawa, Tadao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271944/ https://www.ncbi.nlm.nih.gov/pubmed/32518870 http://dx.doi.org/10.1016/j.ekir.2020.03.030

Ejemplares similares

Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in patients with diabetic kidney disease: design and baseline characteristics of the AYAME study
por: Nangaku, Masaomi, et al.
Publicado: (2022)

Bardoxolone methyl: drug development for diabetic kidney disease
por: Kanda, Hironori, et al.
Publicado: (2020)

Antioxidants in Kidney Diseases: The Impact of Bardoxolone Methyl
por: Rojas-Rivera, Jorge, et al.
Publicado: (2012)

eGFR slope as a surrogate endpoint for clinical study in early stage of chronic kidney disease: from The Japan Chronic Kidney Disease Database
por: Itano, Seiji, et al.
Publicado: (2023)

A Phase 3 Study of Enarodustat in Anemic Patients with CKD not Requiring Dialysis: The SYMPHONY ND Study
por: Akizawa, Tadao, et al.
Publicado: (2021)

Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial
por: Inaba, Masaaki, et al.
Publicado: (2021)

Safety of daprodustat in patients with anemia of chronic kidney disease: A pooled analysis of phase 3 studies in Japan
por: Nangaku, Masaomi, et al.
Publicado: (2022)

Effect of Tenapanor on Phosphate Binder Pill Burden in Hemodialysis Patients
por: Akizawa, Tadao, et al.
Publicado: (2021)

Two long‐term phase 3 studies of enarodustat (JTZ‐951) in Japanese anemic patients with chronic kidney disease not on dialysis or on maintenance hemodialysis: SYMPHONY ND‐Long and HD‐Long studies
por: Akizawa, Tadao, et al.
Publicado: (2021)

Anticholestatic Effect of Bardoxolone Methyl on Hepatic Ischemia-reperfusion Injury in Rats
por: Kim, Joohyun, et al.
Publicado: (2020)

Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan
por: Tanaka, Tetsuhiro, et al.
Publicado: (2018)

In vitro study on effect of bardoxolone methyl on cisplatin-induced cellular senescence in human proximal tubular cells
por: Kurosaki, Yoshifumi, et al.
Publicado: (2022)

Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease
por: Sun, Qi, et al.
Publicado: (2021)

Higher hemoglobin levels using darbepoetin alfa and kidney outcomes in advanced chronic kidney disease without diabetes: a prespecified secondary analysis of the PREDICT trial
por: Maruyama, Shoichi, et al.
Publicado: (2023)

Impact of Pregnancy on GFR Decline and Kidney Histology in Kidney Transplant Recipients
por: Kattah, Andrea G., et al.
Publicado: (2021)

Bardoxolone Methyl Prevents Mesenteric Fat Deposition and Inflammation in High-Fat Diet Mice
por: Dinh, Chi H. L., et al.
Publicado: (2015)

Bardoxolone methyl analog attenuates proteinuria-induced tubular damage by modulating mitochondrial function
por: Nagasu, Hajime, et al.
Publicado: (2019)

Bardoxolone methyl ameliorates osteoarthritis by inhibiting osteoclastogenesis and protecting the extracellular matrix against degradation
por: Yang, Ruijia, et al.
Publicado: (2023)

Cardiac and renal function in patients with type 2 diabetes who have chronic kidney disease: potential effects of bardoxolone methyl
por: McCullough, Peter A, et al.
Publicado: (2012)

In Reply to “Letter Regarding ‘Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial’”
por: Inaba, Masaaki, et al.
Publicado: (2022)

Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties
por: Wang, Yan-Yang, et al.
Publicado: (2014)

Bardoxolone methyl inhibits the infection of rabies virus via Nrf2 pathway activation in vitro
por: Chi, Ying Lin, et al.
Publicado: (2023)

Initial responsiveness to darbepoetin alfa and its contributing factors in non-dialysis chronic kidney disease patients in Japan
por: Hayashi, Terumasa, et al.
Publicado: (2020)

Assessing GFR With Proenkephalin
por: Beunders, Remi, et al.
Publicado: (2023)

Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial)
por: Kato, Hideki, et al.
Publicado: (2017)

Effects of Bardoxolone Methyl on Hepatic Enzymes in Patients with Type 2 Diabetes Mellitus and Stage 4 CKD
por: Lewis, James H., et al.
Publicado: (2020)

Bardoxolone conjugation enables targeted protein degradation of BRD4
por: Tong, Bingqi, et al.
Publicado: (2020)

Bardoxolone methyl induces apoptosis and autophagy and inhibits epithelial-to-mesenchymal transition and stemness in esophageal squamous cancer cells
por: Wang, Yan-Yang, et al.
Publicado: (2015)

Bardoxolone-Methyl Prevents Oxidative Stress-Mediated Apoptosis and Extracellular Matrix Degradation in vitro and Alleviates Osteoarthritis in vivo
por: Pang, Zhiying, et al.
Publicado: (2021)

Repeated glucose spikes and insulin resistance synergistically deteriorate endothelial function and bardoxolone methyl ameliorates endothelial dysfunction
por: Ogiso, Kazuma, et al.
Publicado: (2022)

Bardoxolone-Methyl (CDDO-Me) Impairs Tumor Growth and Induces Radiosensitization of Oral Squamous Cell Carcinoma Cells
por: Hermann, Cornelius, et al.
Publicado: (2021)

Bardoxolone Methyl Ameliorates Myocardial Ischemia/Reperfusion Injury by Activating the Nrf2/HO-1 Signaling Pathway
por: Huang, Anwu, et al.
Publicado: (2023)

Absent or diminished pedal pulses and estimated GFR decline in patients with diabetic kidney disease
por: Subramanian, Nivetha, et al.
Publicado: (2019)

The Longitudinal Study of Liver Cysts in Patients With Autosomal Dominant Polycystic Kidney Disease and Polycystic Liver Disease
por: Matsuura, Ryo, et al.
Publicado: (2016)

Use of the Renal Angina Index in Determining Acute Kidney Injury
por: Matsuura, Ryo, et al.
Publicado: (2018)

GFR Estimation in Potential Living Kidney Donors: Race- and Nonrace-based Equations and Measured GFR
por: Goodson, David Alex, et al.
Publicado: (2022)

Using estimated glomerular filtration rate (eGFR) to help manage patients with chronic kidney disease
por: Courtney, Aisling E, et al.
Publicado: (2007)

The Effects of Two Nrf2 Activators, Bardoxolone Methyl and Omaveloxolone, on Retinal Ganglion Cell Survival during Ischemic Optic Neuropathy
por: Chien, Jia-Ying, et al.
Publicado: (2021)

Bardoxolone Methyl Ameliorates Compression-Induced Oxidative Stress Damage of Nucleus Pulposus Cells and Intervertebral Disc Degeneration Ex Vivo
por: Tian, Yueyang, et al.
Publicado: (2022)

Randomized Study of Tenapanor Added to Phosphate Binders for Patients With Refractory Hyperphosphatemia
por: Nitta, Kosaku, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4lh959pvr75fpre95i4i9llbad